Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report

Camci C., Sevinc A., Aslan Y., Kalender M. E., Buyukberber S.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.63, no.4, pp.745-748, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 63 Issue: 4
  • Publication Date: 2009
  • Doi Number: 10.1007/s00280-008-0775-x
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.745-748
  • Keywords: Ovarian cancer, Complete remission, Tegafur with uracil, SERUM CA-125 LEVELS, CHEMOTHERAPY, TRIAL
  • Gazi University Affiliated: Yes


Background Ovarian cancer remains one of the most lethal of all gynecologic malignancies, accounting for more deaths than cervical and uterine cancer combined. Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses. However, despite aggressive surgery and chemotherapy, more than 80% of patients will relapse and will then be treated with second line chemotherapy with objective responses in about 20% of patients and even lower percentages of complete responses.